Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026

Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026

Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027

PHILADELPHIA, March 23, 2026(GLOBE NEWSWIRE)-- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights.

“We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors. We are on track to provide Phase 1a interim data for our CTIM-76 trial in June 2026. We are also continuing dose escalation for CT-95 toward target dose levels and expect to provide Phase 1a interim data for this trial in September 2026. Looking ahead, we anticipate dosing the first patient in our CT-202 Phase 1 trial in the third quarter of 2026,” said Martin Lehr, CEO of Context.

“Supported by an expected cash runway extending into mid-2027, we remain focused on execution and believe we are positioned to deliver multiple clinical updates throughout the remainder of 2026.” concluded Mr. Lehr.

Pipeline Highlights

Corporate Highlights

About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visitwww.contexttherapeutics.comor follow the Company onX(formerly Twitter) andLinkedIn.

Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the Company’s expectation to provide Phase 1a interim data, and host a webinar to present data, for CTIM-76 in June 2026, (ii) the Company’s expectation to provide Phase 1a interim data, and host a webinar to present data, for CT-95 in September 2026, (iii) the Company’s expectation to dose the first patient in its Phase 1 trial for CT-202 in the third quarter of 2026, (iv) the Company’s expectation to have sufficient cash and cash equivalents to fund its operations into mid-2027, (v) the Company’s expectation to deliver clinical updates throughout the remainder of 2026, (vi) the potential benefits, characteristics, and side effect profile of the Company’s product candidates, (vii) the ability of the Company’s product candidates to have benefits, characteristics, and a side effect profile that is differentiated and/or better than third party product candidates, (viii) the likelihood data will support future development, and (ix) the likelihood of obtaining regulatory approval of the Company’s product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and the Company therefore cannot assure the reader that its plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.